Advanced Therapy Medicines Based on Oncolytic Viruses (Part II: Development and Authorisation of IMLYGIC®)

The only oncolytic virus-based product authorised in the US and EU—IMLYGIC^®, a genetically modified herpes simplex virus type 1 (by BioVex Inc., a subsidiary of Amgen, Inc.)—was developed and approved for clinical use as monotherapy for recurrent unresectable melanoma. The aim of the study was to analyse materials on IMLYGIC^® development and authorisation in order to be able to use the data on specific aspects of preclinical and clinical trials of oncolytic virus-based products in the development of regulatory framework for Russia and the EAEU. The publicly available preclinical and clinical trial results demonstrate a decrease in the size of both tumours being injected and remote tumours/skin lesions, which supports the local and systemic effects of IMLYGIC^® due to the lysis effect of the virus on the tumour cells. The clinical trials of IMLYGIC^® were the first to use the durable response rate, and not the overall survival, as the primary endpoint of the efficacy of the anticancer drug. Benefits of IMLYGIC^® therapy were observed across all the secondary endpoints, except overall survival. Significant efficacy of the drug therapy was demonstrated only in patients without visceral lesions, which resulted in limitations of indications for use. There have been no serious or severe adverse effects associated with IMLYGIC^®. If symptoms of viral infection develop, they can be neutralized thanks to the product’s sensitivity to acyclovir. At present, advanced therapy medicinal products derived from an oncolytic virus may be authorised in Russia for clinical use as monotherapy or combination therapy, according to the EAEU regulations.

1. Мельникова ЕВ, Рачинская ОА, Меркулов ВА. Высокотехнологические лекарственные препараты на основе онколитических вирусов (часть 1: разработка и регистрация в КНР). Ведомости Научного центра экспертизы средств медицинского применения. 2021;11(3):148–59. [Melnikova EV, Rachinskaya OA, Merkulov VA. Advanced therapy medicines based on oncolytic viruses (part I: development and authorisation of products in China). Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2021;11(3):148–59 (In Russ.)] https://doi.org/10.30895/1991-2919-2021-11-148-159

2. Cybulska-Stopa B, Skoczek M, Ziobro M, Świtaj T, Falkowski S, Morysiński T, et al. Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV. Contemp Oncol (Pozn). 2012;16(6):532–45. https://doi.org/10.5114/wo.2012.32487

3. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8. https://doi.org/10.1200/JCO.2014.58.3377

4. Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, Ӧhrling K, Kaufman HL. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 2019;7(1):145. https://doi.org/10.1186/s40425-019-0623-z

5. Harrington KJ, Kong A, Mach N, Chesney JA, Fernandez BC, Rischin D, et al. Talimogene laherparepvec and Pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTERKEY-232): a multicenter, phase 1b study. Clin Cancer Res. 2020;26(19):5153–61. https://doi.org/10.1158/1078-0432.CCR-20-1170

6. Kelly CM, Antonescu CR, Bowler T, Munhoz R, Chi P, Dickson MA, et al. Objective response rate among patients with locally advanced or metastatic sarcoma treated with Talimogene laherparepvec in combination with Pembrolizumab: a phase 2 clinical trial. JAMA Oncol. 2020;6(3):402–8. https://doi.org/10.1001/jamaoncol.2019.6152

7. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–19.e10. https://doi.org/10.1016/j.cell.2017.08.027

8. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of Talimogene laherparepvec in combination with Ipilimumab versus Ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 2018;36(17):1658–67. https://doi.org/10.1200/JCO.2017.73.7379

9. Chesney J, Puzanov I, Collichio F, Milhem MM, Hauschild A, Chen L, et al. Patterns of response with Talimogene laherparepvec in combination with Ipilimumab or Ipilimumab alone in metastatic unresectable melanoma. Br J Cancer. 2019;121(5):417–20. https://doi.org/10.1038/s41416-019-0530-6

10. Меркулов ВА, Мельникова ЕВ. Биомедицинские клеточные продукты или высокотехнологические лекарственные препараты. БИОпрепараты. Профилактика, диагностика, лечение. 2019;19(2):94–8 [Merkulov VA, Melnikova EV. Biomedical cell products or high-tech drugs? BIOpreparaty. Profilaktika, diagnostika, lechenie = BIOpreperations. Prevention, Diagnosis, Treatment. 2019;19(2):94–8 (In Russ.)] https://doi.org/10.30895/2221-996X-2019-19-2-94-98